Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm nab-paclitaxel salvage therapy trial in advanced gastric or gastro-esophageal junction adenocarcinoma
2012-002179-32Phase 2Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Hellenic Oncology Research Group. Primary endpoint: Objective response rate. Started Aug 2012; status: completed.
02
Drugs
paclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2012-002179-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002179-32.